

# Key Pimozide Tablet Market Driver 2024-2033: Rising Healthcare Expenditure

The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only!

LONDON, GREATER LONDON, UNITED KINGDOM, December 15, 2024 /EINPresswire.com/ -- Take advantage of The Business Research Company's early year-end sale! Get up to 30% off



detailed market research reports—for a limited time only!

So, what growth has the pimozide tablet market recently experienced and expected to demonstrate in the future?



The pimozide tablet market size is expected to see strong growth in the next few years. It will grow to \$2.43 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%"

The Business Research
Company

The pimozide tablet market recently witnessed strong growth. The market is set to increase from \$1.52 billion in 2023 to \$1.67 billion in 2024, marking a compound annual growth rate CAGR of 9.7%. Key contributors to this historical growth include increased mental disorder diagnoses, rising mental health awareness, better insurance coverage, improved healthcare infrastructure, and demographic shifts towards a larger geriatric population.

Curious for more details? You can explore a comprehensive summary of the pimozide tablet market

#### here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19655&type=smp

What else can we anticipate for pimozide tablet market growth over the next several years? The pimozide tablet market size is projected for significant growth over the next few years. The market is estimated to reach \$2.43 billion in 2028 at a compound annual growth rate CAGR of 9.8%. Expected growth can be attributed to improvements in mental health services accessibility, increasing disposable incomes, entry of generic versions of mental disorder drugs, new

regulatory approvals and label expansions, and enhanced management and reduction of side effects.

Can you tell me more about the main market trends forecasted for the next few years? Sure! Emerging market trends in the forecast period incorporate technological advancements and the emergence of e-commerce platforms. These advancements will supplement diagnostic techniques for psychiatric disorders, promote market penetration in emerging economies, and stimulate growth of telemedicine and online consultations.

So, what are the main <u>drivers propelling the growth of the pimozide tablet market?</u> Increasing prevalence of psychiatric disorders will likely act as a major driver to the growth of the pimozide tablet market. Psychiatric disorders are mental health conditions that create disturbances in thoughts, emotions, restricting everyday functionality. These disorders have primarily surfaced due to mounting stress levels, shifting societal norms, greater awareness and improved diagnoses, and genetic predispositions. Pimozide tablets are typically used to manage psychiatric disorder symptoms such as delusions and tics by inhibiting dopamine receptors and reducing abnormal brain activity.

Moreover, the number of dementia cases globally are on the rise. The NCD Alliance, a Switzerland-based civil society network, reported in February 2022 that 55 million people were living with dementia globally. Nearly 10 million new cases are expected each year, with the total reaching approximately 75 million by 2030 and 139 million by 2050. The rising prevalence of psychiatric disorders is, therefore, a pivotal driver in pimozide tablet market growth.

Secure insightful forecasts, comprehensive market analysis, and strategic insights with the pimozide tablet market global report here:

https://www.thebusinessresearchcompany.com/report/pimozide-tablet-global-market-report

What key players are operating in the pimozide tablet market?

Many major companies operate in the pimozide tablet market, including Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Bristol-Myers Squibb, GlaxoSmithKline plc, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Hetero Drugs, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Aurobindo Pharma, Cipla Limited, Apotex Inc., H. Lundbeck A/S, Dr. Reddy's Laboratories, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Endo International, Lupin Limited, Zydus Cadila, Alkem Laboratories, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Mallinckrodt Pharmaceuticals, Jubilant Life Sciences, Alembic Pharmaceuticals, Wockhardt, AA Pharma, and Taj Pharmaceuticals.

And how is the pimozide tablet market segmented?

The pimozide tablet market report is divided based on the following segments -

- 1 By Type: 1 Milligram, 2 Milligram, 4 Milligram
- 2 By Distribution Channel: Online, Offline
- 3 By Application: Tourette's Syndrome, Chronic Schizophrenia

4 By End User: Hospitals, Clinics, Home Use.

Can you give us some insight into the regional landscape of the pimozide tablet market? Absolutely! North America held the largest share in the pimozide tablet market in 2023. Other regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company: Effervescent Tablet Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Methenamine Hippurate Tablets Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report

Oil-Based Printing Inks Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oil-based-printing-inks-global-market-report

### **About The Business Research Company**

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

#### Contact us at:

The Business Research Company: <a href="https://www.thebusinessresearchcompany.com/">https://www.thebusinessresearchcompany.com/</a>

Americas: +1 3156230293 Asia: +44 2071930708 Europe: +44 2071930708 Email us at info@tbrc.info

Stay connected:

LinkedIn: <a href="https://in.linkedin.com/company/the-business-research-company/">https://in.linkedin.com/company/the-business-research-company/</a> YouTube: <a href="https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ">https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ</a>

Global Market Model: <a href="https://www.thebusinessresearchcompany.com/global-market-model">https://www.thebusinessresearchcompany.com/global-market-model</a>

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:

Facebook

## X

#### LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/768417914

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.